TNXP Tonix Pharmaceuticals Holding: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Tonix Pharmaceuticals (TNXP) relies on diversified CNS research and government support to maintain liquidity. Management is coordinating the parallel launch of multiple clinical stages, although frequent secondary offerings and test failures are weakening patent protection. This daily price action reflects these factors, recording the 0.00 metric, which underscores the company's current fundamental state.

For Tonix Pharmaceuticals (TNXP), which competes in the pain management drug segment, fluctuations in the company's EV/EBITDA ratio reflect the business value relative to its operational efficiency. This multiple is calculated as the ratio of total enterprise value to earnings before interest, taxes, depreciation, and amortization. The formula's high sensitivity to debt load reveals risks associated with the acceleration of costly research. The stability of this indicator determines the asset's ability to withstand market shocks.